ME00514B - Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu - Google Patents

Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu

Info

Publication number
ME00514B
ME00514B MEP-2008-842A MEP84208A ME00514B ME 00514 B ME00514 B ME 00514B ME P84208 A MEP84208 A ME P84208A ME 00514 B ME00514 B ME 00514B
Authority
ME
Montenegro
Prior art keywords
active substance
amorphous active
pharmaceutical preparation
stabilized pharmaceutical
amorphous
Prior art date
Application number
MEP-2008-842A
Other languages
English (en)
French (fr)
Inventor
Andrej Bastarda
Mateja Salobir
Rok Grahek
Original Assignee
Lek Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00514(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals filed Critical Lek Pharmaceuticals
Publication of ME00514B publication Critical patent/ME00514B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pronalazak se odnosi na farmaceutski preparat koji sadrži amorfnu aktivnu supstancu izloženu atmosferi inertnog gasa. Opisani su postupak stabilizacije farmaceutskog preparata koji sadrži farmaceutsku formulaciju sa amorfnom aktivnom supstancom, postupak stabilizacije farmaceutske formulacije koja sadrži amorfnu aktivnu supstancu kao i postupak stabilizacije amorfne aktivne supstance. Amorfna aktivna supstanca može biti amorfni atorvastatin.
MEP-2008-842A 2002-10-11 2003-10-10 Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu ME00514B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PCT/EP2003/011265 WO2004032920A1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance

Publications (1)

Publication Number Publication Date
ME00514B true ME00514B (me) 2011-10-10

Family

ID=32091984

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-842A ME00514B (me) 2002-10-11 2003-10-10 Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu

Country Status (21)

Country Link
US (2) US20040077708A1 (me)
EP (1) EP1608362B1 (me)
CN (1) CN100372529C (me)
AR (1) AR041588A1 (me)
AT (2) ATE354362T1 (me)
AU (1) AU2003280361B2 (me)
CY (1) CY1106608T1 (me)
CZ (1) CZ17610U1 (me)
DE (2) DE20321455U1 (me)
DK (2) DK1608362T3 (me)
ES (1) ES2285205T3 (me)
FI (1) FI7617U1 (me)
ME (1) ME00514B (me)
PT (1) PT1608362E (me)
RS (1) RS51819B (me)
RU (1) RU2358727C2 (me)
SI (2) SI21302A (me)
SK (1) SK5233Y1 (me)
TW (1) TWI320709B (me)
UA (1) UA85544C2 (me)
WO (1) WO2004032920A1 (me)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2002351271A1 (en) 2001-12-21 2003-07-24 Nektar Therapeutics Capsule package with moisture barrier
ATE381322T1 (de) * 2003-08-05 2008-01-15 Zentiva As Verfahren zur stabilisierung von atorvastatin
CA2627940A1 (en) 2004-03-17 2005-10-06 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
EP1793815A4 (en) * 2004-09-30 2010-12-29 Reddys Lab Ltd Dr AMORPHES ATORVASTATINCALCIUM
EP1819319A1 (en) * 2004-12-02 2007-08-22 Warner-Lambert Company LLC Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
WO2011077843A1 (ja) 2009-12-25 2011-06-30 沢井製薬株式会社 アトルバスタチン含有被覆製剤
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
WO2016126860A1 (en) * 2015-02-03 2016-08-11 Kadmon Pharmaceuticals, Llc Stable trientine formulations
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (me) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CA2201354A1 (en) * 1994-09-30 1996-04-11 Becton, Dickinson And Company Method for forming and packaging iontophoretic drug delivery patches and the like to increase stability and shelf-life
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
EP1296672B2 (en) * 2000-06-09 2018-10-24 LEK Pharmaceuticals d.d. Stable pharmaceutical product and formulation
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs

Also Published As

Publication number Publication date
PT1608362E (pt) 2007-05-31
RS20050273A (en) 2007-06-04
RS51819B (sr) 2011-12-31
ES2285205T3 (es) 2007-11-16
AT10424U1 (de) 2009-03-15
US20040077708A1 (en) 2004-04-22
WO2004032920A1 (en) 2004-04-22
CN1703215A (zh) 2005-11-30
US20090012150A1 (en) 2009-01-08
SI1608362T1 (sl) 2007-12-31
CZ17610U1 (cs) 2007-06-18
EP1608362B1 (en) 2007-02-21
FIU20070036U0 (fi) 2007-01-26
DE60312049D1 (de) 2007-04-05
CY1106608T1 (el) 2012-01-25
ATE354362T1 (de) 2007-03-15
RU2005114485A (ru) 2006-01-27
AU2003280361B2 (en) 2009-02-26
AU2003280361A1 (en) 2004-05-04
FI7617U1 (fi) 2007-09-28
TWI320709B (en) 2010-02-21
EP1608362A1 (en) 2005-12-28
AR041588A1 (es) 2005-05-26
DE20321455U1 (de) 2007-05-24
TW200501947A (en) 2005-01-16
CN100372529C (zh) 2008-03-05
SI21302A (sl) 2004-04-30
DE60312049T2 (de) 2007-10-04
DK1608362T3 (da) 2007-05-14
DK200700025U4 (da) 2008-03-14
RU2358727C2 (ru) 2009-06-20
SK5233Y1 (en) 2009-09-07
DK200700025U1 (da) 2007-06-08
UA85544C2 (ru) 2009-02-10
SK50062007U1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
ME00514B (me) Stabilizovani farmaceutski preparat koji sadrži amorfnu aktivnu supstancu
IS7543A (is) Bensóþíadíasepínafleiður, aðferðir til framleiðslu þeirra og lyfjablöndur sem innihalda þær
EA200801859A1 (ru) Неводная композиция стабильного витамина "c", способ ее приготовления и применения
IS8024A (is) Adamantanafleiður, aðferðir til að framleiða þær og lyfjablanda sem inniheldur þær
CY1113011T1 (el) Νεα κρυσταλλικη μορφη v της αγομελατινης, μεθοδος παρασκευης αυτης και φαρμακευτικες συνθεσεις που περιεχουν αυτην
NO20054789D0 (no) Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon
NO20034490D0 (no) Fremgangsmåte for sammensetting av absorberende gjenstand til personlig stell
DK1501485T3 (da) Tablet med höjt indhold af aktivt stof
NO20050741D0 (no) Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
PA8577901A1 (es) Formulacion farmaceutica
AU2002366313A1 (en) Solid compositions containng compounds unstable to oxygen and method for stabilization thereof
NO20052494D0 (no) Preparater inneholdende melatonin, gingko biloba og biotin.
ATE497489T1 (de) Nichtsymmetrisches geliermittel
UA87335C2 (en) Gel composition of 4-hydroxytamoxifen
NO20064934L (no) Fremgangsmate for fremstilling av et fast, farmasoytisk preparat
ATE403425T1 (de) Feste formulierungen enthaltend eine indolinon verbindung
WO2004078105A3 (fr) Composition de fondaparinux sodique de haute purete
CY1107028T1 (el) Παραγωγα ινδανυλ-πιπεραζινων μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
NO20042563L (no) Preparatsammensetning som inneholder syreustabile fysiologisk aktive forbindelser og fremgangsmater til fremstilling derav
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
GB2440102A (en) Fragrance compositions
EA200801572A1 (ru) Фармацевтическая композиция, содержащая аморфный аторвастатин
DK1944291T3 (da) Optisk aktiv cyklisk alkoholforbindelse og fremgangsmåde til at producere samme